Humana · Hizentra CIDP · US health-plan appeal rights

Hizentra CIDP denied as experimental or investigational by Humana?

Q: How long do I have to appeal a Humana Hizentra CIDP denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

An experimental denial requires the appeal to cite the FDA approval (if any), peer-reviewed phase III data, and the recognised specialty-society guideline that supports the treatment for your indication.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-05-11

Policy data current as of 2026-04-26

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Humana typically requires

Humana's specific coverage criteria for hizentra cidp are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

Source policy: Humana Hizentra (Immune Globulin Subcutaneous) for CIDP Maintenance

The Humana angle on Hizentra CIDP

## Why Humana May Deny Hizentra for CIDP as "Experimental"

A denial of Hizentra (subcutaneous immune globulin) for CIDP on grounds of "experimental" or "investigational" is substantively incorrect as a matter of regulatory fact: Hizentra carries FDA approval for the maintenance treatment of CIDP in adults. When Humana applies an experimental/investigational label to an FDA-approved drug used in its approved indication, the denial is typically the result of an outdated coverage policy, a miscoded claim, or a policy that has not yet been updated to reflect the approval.

This type of denial is highly appealable. Your first step is to obtain the FDA-approved prescribing label for Hizentra and confirm that the prescribed use matches the labeled CIDP indication. That label excerpt, combined with a prescriber letter, is usually sufficient to overturn an experimental denial at the internal appeal level.

## Federal Appeal Rights

ACA §2719 / external review: An experimental/investigational denial is subject to mandatory external review under the ACA. An Independent Review Organization (IRO) must apply current clinical evidence and FDA-approval status — not just the plan's internal policy language. File within approximately four months of the denial date (confirm the exact deadline in your denial letter). Expedited review is available for urgent situations.
ERISA §503: Requires Humana to state the specific criteria applied and to conduct a full-and-fair review.

## What to Gather

1. FDA prescribing label — the current label for Hizentra, with the CIDP maintenance indication highlighted. 2. Diagnosis confirmation — neurology notes, nerve conduction studies, or other objective testing establishing the CIDP diagnosis. 3. Prescriber medical-necessity letter — states that Hizentra is being prescribed within its FDA-approved indication for CIDP maintenance and references the applicable professional society guideline organization (e.g., the American Academy of Neurology) generically. 4. Humana's experimental/investigational policy — request a copy and address each stated criterion, particularly any that conflict with the FDA approval status. 5. Clinical history — prior CIDP treatment course and response, supporting the need for ongoing maintenance therapy.

## Criteria-Mapping Structure

| Humana "Experimental" Criterion | Rebuttal Evidence | |---|---| | Each stated basis for the denial | FDA label section, prescriber note, or guideline reference |

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Humana appeals

Other denial reasons for Humana Hizentra CIDP

denied as not medically necessary denied for failing step therapy denied as non-formulary denied for missing prior authorization denied as not FDA-approved for this use

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-05-11. Editorial standards: denialhelp.com/authors.